These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 24104707)
1. Intravitreal anti-VEGF monotherapy for thick submacular hemorrhage of less than 1 week duration secondary to neovascular age-related macular degeneration. Jain S; Kishore K; Sharma YR Indian J Ophthalmol; 2013 Sep; 61(9):490-6. PubMed ID: 24104707 [TBL] [Abstract][Full Text] [Related]
2. Intravitreal anti-vascular endothelial growth factor monotherapy for large submacular hemorrhage secondary to neovascular age-related macular degeneration. Kim HS; Cho HJ; Yoo SG; Kim JH; Han JI; Lee TG; Kim JW Eye (Lond); 2015 Sep; 29(9):1141-51. PubMed ID: 26272443 [TBL] [Abstract][Full Text] [Related]
3. The role of pigment epithelial detachment in AMD with submacular hemorrhage treated with vitrectomy and subretinal co-application of rtPA and anti-VEGF. Treumer F; Wienand S; Purtskhvanidze K; Roider J; Hillenkamp J Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1115-1123. PubMed ID: 28280989 [TBL] [Abstract][Full Text] [Related]
4. Long-term outcome of subretinal coapplication of rtPA and bevacizumab followed by repeated intravitreal anti-VEGF injections for neovascular AMD with submacular haemorrhage. Treumer F; Roider J; Hillenkamp J Br J Ophthalmol; 2012 May; 96(5):708-13. PubMed ID: 22174095 [TBL] [Abstract][Full Text] [Related]
5. Clinical Outcomes of Eyes with Submacular Hemorrhage Secondary to Age-related Macular Degeneration Treated with Anti-vascular Endothelial Growth Factor. Kim KH; Kim JH; Chang YS; Lee TG; Kim JW; Lew YJ Korean J Ophthalmol; 2015 Oct; 29(5):315-24. PubMed ID: 26457037 [TBL] [Abstract][Full Text] [Related]
6. The Timing of Large Submacular Hemorrhage Secondary to Age-Related Macular Degeneration Relative to Anti-VEGF Therapy. Matsunaga DR; Su D; Sioufi K; Obeid A; Wibbelsman T; Ho AC; Regillo CD Ophthalmol Retina; 2021 Apr; 5(4):342-347. PubMed ID: 32763426 [TBL] [Abstract][Full Text] [Related]
7. One-year outcomes of less frequent bevacizumab in age-related macular degeneration. Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363 [TBL] [Abstract][Full Text] [Related]
8. Baseline Predictors for Good Versus Poor Visual Outcomes in the Treatment of Neovascular Age-Related Macular Degeneration With Intravitreal Anti-VEGF Therapy. Chae B; Jung JJ; Mrejen S; Gallego-Pinazo R; Yannuzzi NA; Patel SN; Chen CY; Marsiglia M; Boddu S; Freund KB Invest Ophthalmol Vis Sci; 2015 Aug; 56(9):5040-7. PubMed ID: 26237196 [TBL] [Abstract][Full Text] [Related]
9. Displacement of Submacular Hemorrhage Using Subretinal Cocktail Injection versus Pneumatic Displacement: A Real-World Comparative Study. Szeto SKH; Tsang CW; Mohamed S; Lee GKY; Lok JKH; Hui VWK; Tsang KK; Chen LJ; Brelen M; Lai TYY Ophthalmologica; 2024; 247(2):118-132. PubMed ID: 38408445 [TBL] [Abstract][Full Text] [Related]
10. Management of submacular hemorrhage secondary to neovascular age-related macular degeneration with anti-vascular endothelial growth factor monotherapy. Shienbaum G; Garcia Filho CA; Flynn HW; Nunes RP; Smiddy WE; Rosenfeld PJ Am J Ophthalmol; 2013 Jun; 155(6):1009-13. PubMed ID: 23465269 [TBL] [Abstract][Full Text] [Related]
11. Anti-vascular endothelial growth factor monotherapy in the treatment of submacular hemorrhage secondary to polypoidal choroidal vasculopathy. Cho HJ; Koh KM; Kim HS; Lee TG; Kim CG; Kim JW Am J Ophthalmol; 2013 Sep; 156(3):524-531.e1. PubMed ID: 23769197 [TBL] [Abstract][Full Text] [Related]
16. Anti-VEGF-refractory exudative age-related macular degeneration: differential response according to features on optical coherence tomography. Shin JY; Woo SJ; Ahn J; Park KH Korean J Ophthalmol; 2013 Dec; 27(6):425-32. PubMed ID: 24311928 [TBL] [Abstract][Full Text] [Related]
17. [Intravitreal bevacizumab in AMD complicated by submacular hemorrhage]. Bouraoui R; Bouladi M; Kort F; Limaiem R; Mghaieth F; El Matri L J Fr Ophtalmol; 2016 Mar; 39(3):248-54. PubMed ID: 26995076 [TBL] [Abstract][Full Text] [Related]
18. Intravitreal anti-vascular endothelial growth factor for submacular hemorrhage from choroidal neovascularization. Kim JH; Chang YS; Kim JW; Kim CG; Yoo SJ; Cho HJ Ophthalmology; 2014 Apr; 121(4):926-35. PubMed ID: 24342019 [TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage. Stifter E; Michels S; Prager F; Georgopoulos M; Polak K; Hirn C; Schmidt-Erfurth U Am J Ophthalmol; 2007 Dec; 144(6):886-892. PubMed ID: 17916314 [TBL] [Abstract][Full Text] [Related]
20. Associations and Outcomes of Patients with Submacular Hemorrhage Secondary to Age-related Macular Degeneration in the IVAN Trial. Mehta A; Steel DH; Muldrew A; Peto T; Reeves BC; Evans R; Chakravarthy U; Am J Ophthalmol; 2022 Apr; 236():89-98. PubMed ID: 34626573 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]